• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sinobiomed, Inc. - Product Pipeline Review - Q4 2010 Product Image

Sinobiomed, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 29 pages
  • GlobalData

Sinobiomed, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Sinobiomed, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sinobiomed, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sinobiomed, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across READ MORE >



List of Tables
List of Figures
Sinobiomed, Inc. Snapshot
Sinobiomed, Inc. Overview
Key Information
Key Facts
Sinobiomed, Inc. – Research and Development Overview
Key Therapeutic Areas
Sinobiomed, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Sinobiomed, Inc. – Pipeline Products Glance
Sinobiomed, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Sinobiomed, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sinobiomed, Inc. – Drug Profiles
Etheophazine
Product Description
Mechanism of Action
R&D Progress
PfCP2.9
Product Description
Mechanism of Action
R&D Progress
rBAT
Product Description
Mechanism of Action
R&D Progress
Rh-SCF
Product Description
Mechanism of Action
R&D Progress
Sinobiomed, Inc. – Pipeline Analysis
Sinobiomed, Inc. – Pipeline Products by Therapeutic Class
Sinobiomed, Inc. Pipeline Products By Target
Sinobiomed, Inc. – Pipeline Products by Molecule Type
Sinobiomed, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
May 14, 2008: Sinobiomed’s Announces Initiation Of Phase II Clinical Trial Of Malaria Candidate Vaccine PfCP2.9 In Q3
Nov 29, 2007: Sinobiomed Updates On Clincial Trial Progress For Malaria Vaccine PfCP2.9, rBAT, Etheophazine AND rhk1
Oct 09, 2007: Sinobiomed Subsidiary Obtains Chinese Patent For Recombinant Hepato Regeneration Factor
Sep 18, 2007: Sinobiomed Updates On Clincial Trial Success For Recombinant Batroxobin (rBat)
Jul 31, 2007: Sinobiomed’s Announces Grant Of Australian Patent For Malaria Vaccine PfCP-2.9
Jul 25, 2007: Sinobiomed Announces Patent Grant Of Malaria Vaccine PfCP2.9 In Upto 37 Countries In Europe
Jul 10, 2007: Sinobiomed Updates On Clincial Trial Progress For Recombinant Batroxobin (rBAT)
May 29, 2007: Patent Cooperation Treaty (PCT) Accepts Patent Application From Sinobiomed For Recombinant Batroxobin (rBAT)
Apr 24, 2007: Sinobiomed’s Announces Grant Of US Patent For Malaria Vaccine PfCP2.9
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS